

=> d que

L2 190 SEA FILE=REGISTRY ABB=ON PLU=ON (1042674-02-1/BI OR
 1042674-31-6/BI OR 1042675-60-4/BI OR 10453-86-8/BI OR
 106967-74-2/BI OR 1072-84-0/BI OR 115926-52-8/BI OR
 122-04-3/BI OR 122-59-8/BI OR 129-46-4/BI OR 129318-43-0/BI
 OR 130-15-4/BI OR 13754-19-3/BI OR 145-73-3/BI OR
 146903-18-6/BI OR 150560-58-0/BI OR 15084-51-2/BI OR
 15516-47-9/BI OR 16037-91-5/BI OR 162086-14-8/BI OR
 16629-19-9/BI OR 1710-98-1/BI OR 17325-26-7/BI OR 17630-76-
 1/BI OR 1821-12-1/BI OR 18496-54-3/BI OR 18711-13-2/BI OR
 1878-49-5/BI OR 20142-87-4/BI OR 2058-74-4/BI OR 20780-76-1
 /BI OR 220965-34-4/BI OR 2243-83-6/BI OR 237756-11-5/BI OR
 2632-13-5/BI OR 2650-44-4/BI OR 2687-25-4/BI OR 27318-90-7/
 BI OR 2905-27-3/BI OR 296771-71-6/BI OR 296773-88-1/BI OR
 301166-54-1/BI OR 303092-45-7/BI OR 303149-87-3/BI OR
 303998-01-8/BI OR 304883-18-9/BI OR 311321-81-0/BI OR
 312519-17-8/BI OR 315671-49-9/BI OR 3282-30-2/BI OR
 339205-70-8/BI OR 339205-73-1/BI OR 345630-40-2/BI OR
 345630-42-4/BI OR 36043-49-9/BI OR 376383-76-5/BI OR
 39755-95-8/BI OR 401646-54-6/BI OR 40926-73-6/BI OR
 4122-68-3/BI OR 42494-71-3/BI OR 42494-73-5/BI OR 43100-25-
 0/BI OR 43100-38-5/BI OR 443-69-6/BI OR 452-58-4/BI OR
 458553-48-5/BI OR 4755-77-5/BI OR 477847-81-7/BI OR
 478063-72-8/BI OR 478077-73-5/BI OR 478077-74-6/BI OR
 478077-78-0/BI OR 478077-79-1/BI OR 478257-55-5/BI OR
 478257-73-7/BI OR 478257-76-0/BI OR 484-17-3/BI OR
 496-72-0/BI OR 511518-73-3/BI OR 512796-41-7/BI OR
 512796-49-5/BI OR 512796-50-8/BI OR 512796-65-5/BI OR
 512796-67-7/BI OR 512796-72-4/BI OR 512796-76-8/BI OR
 512796-99-5/BI OR 51630-58-1/BI OR 52315-07-8/BI OR
 524-42-5/BI OR 5271-67-0/BI OR 52918-63-5/BI OR 5315-25-3/B
 I OR 5437-45-6/BI OR 547730-75-6/BI OR 5725-96-2/BI OR
 585557-83-1/BI OR 586-75-4/BI OR 5908-27-0/BI OR 604-95-5/B
 I OR 610-14-0/BI OR 611-09-6/BI OR 619-05-6/BI OR 650620-84
 -1/BI

L7 59167 SEA FILE=REGISTRY ABB=ON PLU=ON 2404.11/RID

L8 512 SEA FILE=REGISTRY ABB=ON PLU=ON L7 AND 9,10-DIOXO?

L10 8 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND PHENOXY?

L11 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L10

L12 32 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND L7

L18 1 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND C14 H9 N O2/MF

L19 1 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND C8 H6 CL2 O2/MF

L20 1 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND C9 H9 CL O2/MF

L21 1 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND C14 H7 N O4/MF

L23 59 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 OR L21

L24 377 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 OR L20

L25 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L23 AND L24

L26 26 SEA FILE=REGISTRY ABB=ON PLU=ON L12 NOT S/ELS

L27 17 SEA FILE=REGISTRY ABB=ON PLU=ON L26 AND 4/NR

L28 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L27

L29 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 OR L28 OR L25

L30 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L23 AND PHARM?/SC, SX

L31 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L29 OR L30


=> d 131 1-8 ibib ed abs hitstr hitind

L31 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:1339565 HCAPLUS Full-text

DOCUMENT NUMBER: 149:509677
 TITLE: Methods and compositions for stem cell self-renewal, particularly hematopoietic stem cell (HSC), by modulating PTEN and Wnt pathways
 INVENTOR(S): Perry, John M.; Li, Linheng; Grindley, Justin C.
 PATENT ASSIGNEE(S): Stowers Institute for Medical Research, USA
 SOURCE: PCT Int. Appl., 110pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008133904	A1	20081106	WO 2008-US5230	20080423
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2007-926065P	P 20070423
			US 2008-66693P	P 20080222

ED Entered STN: 07 Nov 2008
 AB The present invention relates to methods for expanding a stem cell population without significant stem cell differentiation by modulating a PTEN phosphatase pathway and a Wnt pathway. More particularly, the invention relates, to methods and compns. for expanding a stem cell population, particularly a hematopoietic stem cell (HSC) population obtained from peripheral blood, cord blood, or bone marrow. The expanded HSC population comprises cells with a phenotype consisting of CD34-, CD34+/CD38-Thy1+/CD90+/Kit-/Lin-/CD133+/VEGFR2+, CD150+/CD48-/CD244-, CD150-/CD48-/CD244+, CD150-/CD48+/CD244+, and combinations thereof. In one embodiment the invention provides a kit for expanding HSC population for subsequent transplantation into a patient in need thereof. The kit comprises a PTEN inhibitor, a GSK-3 β (glycogen synthase kinase 3 β) inhibitor, and instructions for the use of the inhibitors. It was demonstrated, that loss of PTEN with constitutively active β -catenin leads to HSC expansion with loss of early hematopoietic progenitors. It was also demonstrated, that ex vivo pharmacol. manipulation of the PTEN/Akt and Wnt/ β -catenin signaling pathways cooperatively drive functional HSC expansion.
 IT 867376-02-1, SF 1751
 (reversible PTEN inhibitor; methods and compns. for stem cell self-renewal, particularly hematopoietic stem cell (HSC), by modulating PTEN and Wnt pathways)
 RN 867376-02-1 HCAPLUS
 CN Acetamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-(4-methoxyphenoxy)- (CA INDEX NAME)



CC 13-6 (Mammalian Biochemistry)

Section cross-reference(s): 3, 9, 63

IT 517-89-5, Shikonin 12179-38-3D, derivs. 867376-02-1, SF
1751

(reversible PTEN inhibitor; methods and compns. for stem cell self-renewal, particularly hematopoietic stem cell (HSC), by modulating PTEN and Wnt pathways)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:1243425 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 149:524585

TITLE: Structure-Based Virtual Screening and Biological Evaluation of *Mycobacterium tuberculosis* Adenosine 5'-Phosphosulfate Reductase Inhibitors

AUTHOR(S): Cosconati, Sandro; Hong, Jiyoung A.; Novellino, Ettore; Carroll, Kate S.; Goodsell, David S.; Olson, Arthur J.

CORPORATE SOURCE: Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA

SOURCE: Journal of Medicinal Chemistry (2008), 51(21), 6627-6630

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 16 Oct 2008


AB *Tuberculosis* is among the world's deadliest infectious diseases. APSR reductase catalyzes the first committed step in bacterial sulfate reduction and is a validated drug target against latent tuberculosis infection. We performed a virtual screening to identify APSR inhibitors. These inhibitors represent the first non-phosphate-based mols. to inhibit APSR. Common chemical features lay the foundation for the development of agents that could shorten the duration of chemotherapy by targeting the latent stage of TB infection.

IT 604-95-5

(structure-based screening and evaluation of *M. tuberculosis* APSR inhibitors)

RN 604-95-5 HCAPLUS

CN 9,10-Phenanthrenedione, 2-nitro- (CA INDEX NAME)



CC 1-3 (Pharmacology)

IT 604-95-5 6942-44-5 13287-73-5 58160-29-5 113104-25-9
 500576-09-0 501687-72-5 820999-41-5 873058-04-9 1073524-06-7
 (structure-based screening and evaluation of *M. tuberculosis* APSR
 inhibitors)

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L31 ANSWER 3 OF 8 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1167266 HCPLUS Full-text

DOCUMENT NUMBER: 147:514411

TITLE: Planarity and Constraint of the Carbonyl Groups in
 1,2-Diones Are Determinants for Selective
 Inhibition of Human Carboxylesterase 1

AUTHOR(S): Hyatt, Janice L.; Wadkins, Randy M.; Tsurkan, Lyudmila; Hicks, Latoria D.; Hatfield, M. Jason; Edwards, Carol C.; Ross, Charles R., II; Cantalupo, Stephanie A.; Crundwell, Guy; Danks, Mary K.; Guy, R. Kip; Potter, Philip M.

CORPORATE SOURCE: Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA

SOURCE: Journal of Medicinal Chemistry (2007), 50(23), 5727-5734

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:514411


ED Entered STN: 17 Oct 2007

AB Carboxylesterases (CE) are ubiquitous enzymes responsible for the detoxification of xenobiotics, including numerous clin. used drugs. Therefore, the selective inhibition of these proteins may prove useful in modulating drug half-life and bioavailability. Recently, we identified 1,2-diones as potent inhibitors of CEs, although little selectivity was observed in the inhibition of either human liver CE (hCE1) or human intestinal CE (hiCE). In this paper, we have further examined the inhibitory properties of ethane-1,2-diones toward these proteins and determined that, when the carbonyl oxygen atoms are cis-coplanar, the compds. demonstrate specificity for hCE1. Conversely, when the dione oxygen atoms are not planar (or are trans-coplanar), the compds. are more potent at hiCE inhibition. These properties have been validated in over 40 1,2-diones that demonstrate inhibitory activity toward at least one of these enzymes. Statistical anal. of the results confirms the correlation ($P < 0.001$) between the dione dihedral angle and the preferential inhibition of either hiCE or hCE1. Overall, the results presented here define the parameters necessary for small mol. inhibition of human CEs.

IT 604-95-5

(Planarity and Constraint of the Carbonyl Groups in 1,2-Diones Are

Determinants for Selective Inhibition of Human Carboxylesterase 1)
 RN 604-95-5 HCAPLUS
 CN 9,10-Phenanthrenedione, 2-nitro- (CA INDEX NAME)



CC 1-3 (Pharmacology)
 Section cross-reference(s): 25, 27, 28
 IT 82-86-0, Acenaphthoquinone 84-11-7, 9,10-Phenanthrenedione 134-81-6, Benzil 524-42-5, 1,2-Naphthoquinone 604-95-5 951-88-2, 1,2-Dicyclohexylethane-1,2-dione 1226-42-2 2103-62-0 2132-59-4 2767-84-2, (+/-)-Camphorquinone 3363-97-1 4290-72-6 4746-81-0, Mesitil 6067-45-4 6373-11-1, 1,2-Aceanthrylenedione 6706-92-9 16214-27-0, 1,2-Indandione 24243-31-0, Benzo[1,2-b:4,3-b']dithiophene-4,5-dione 27471-02-9 40261-88-9 65938-98-9, Benzo[h]quinoline-5,6-dione
 (Planarity and Constraint of the Carbonyl Groups in 1,2-Diones Are Determinants for Selective Inhibition of Human Carboxylesterase 1)
 REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1123765 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:405906
 TITLE: Preparation of (heteroaryl) amides and hydrazides as inhibitors of phosphatase located on chromosome 10 (PTEN).
 INVENTOR(S): Garlich, Joseph R.; Durden, Donald L.; Georgiadis, Taxiarchis M.; Su, Jingdong; Peng, Xiaodong; Smith, Tim C.
 PATENT ASSIGNEE(S): Semafore Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097119	A2	20051020	WO 2005-US11626	20050406
WO 2005097119	A3	20060126		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,
 NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2563316 A1 20051020 CA 2005-2563316 20050406
 EP 1755574 A2 20070228 EP 2005-763900 20050406
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
 IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2007532552 T 20071115 JP 2007-507462 20050406
 US 20070203098 A1 20070830 US 2006-599748 20061006
 PRIORITY APPLN. INFO.: US 2004-559802P P 20040406
 US 2004-590043P P 20040720
 US 2004-625871P P 20041108
 WO 2005-US11626 W 20050406

OTHER SOURCE(S): CASREACT 143:405906

ED Entered STN: 20 Oct 2005

GI




AB A method of protecting a patient from ≥1 treatments that trigger apoptosis comprises administration of a pharmaceutically acceptable amount of a PTEN inhibitor. Thus, 1-(6-methyl-2-pyridinyl)-1H-imidazole-4-carbohydrazide was stirred overnight with 2-naphthoyl chloride and Et₃N in CH₂C₁₂ to give title compound (I). I gave 41-43% inhibition of PTEN at 250 μM.

IT 604-95-5P 36043-49-9P 345630-42-4P
 860207-98-1P 867376-01-0P 867376-02-1P
 867376-03-2P 867376-04-3P 867376-07-6P
 867376-10-1P 867376-12-3P 867376-13-4P
 867376-14-5P 867376-15-6P 867376-18-9P
 867376-20-3P 867376-29-2P 867376-34-9P
 867376-35-0P


(preparation of (heteroaryl) amides and hydrazides as inhibitors of phosphatase located on chromosome 10 (PTEN))

RN 604-95-5 HCPLUS


CN 9,10-Phenanthrenedione, 2-nitro- (CA INDEX NAME)




RN 36043-49-9 HCAPLUS
 CN 9,10-Phenanthrenedione, 2-amino- (CA INDEX NAME)




RN 345630-42-4 HCAPLUS
 CN Benzamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-nitro- (CA INDEX NAME)




RN 860207-88-1 HCAPLUS
 CN Benzamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)- (CA INDEX NAME)




RN 867376-01-0 HCAPLUS
 CN Acetamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-phenoxy- (CA INDEX NAME)




RN 867376-02-1 HCAPLUS
 CN Acetamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-(4-methoxyphenoxy)- (CA INDEX NAME)




RN 867376-03-2 HCAPLUS
 CN Acetamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-(4-methylphenoxy)- (CA INDEX NAME)




RN 867376-04-3 HCAPLUS
 CN Acetamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-[2-(1-methylethyl)phenoxy]- (CA INDEX NAME)




RN 867376-07-6 HCAPLUS
 CN Benzamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-4-methyl- (CA INDEX NAME)




RN 867376-10-1 HCAPLUS
 CN Benzenebutanamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)- (CA INDEX NAME)




RN 867376-12-3 HCAPLUS
 CN Acetamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-(2-methoxyphenoxy)- (CA INDEX NAME)




RN 867376-13-4 HCAPLUS
 CN Acetamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-(3-methoxyphenoxy)- (CA INDEX NAME)




RN 867376-14-5 HCAPLUS
 CN Acetamide, 2-(4-chlorophenoxy)-N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)- (CA INDEX NAME)



RN 867376-15-6 HCAPLUS
 CN Acetamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-(2-nitrophenoxy)- (CA INDEX NAME)




RN 867376-18-9 HCAPLUS
 CN 9,10-Phenanthrenedione, 2-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 867376-20-3 HCAPLUS

CN Benzamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-4-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867376-29-2 HCAPLUS

CN Glycine, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-, phenylmethyl ester (CA INDEX NAME)




RN 867376-34-9 HCAPLUS

CN Benzamide, 4-bromo-N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)- (CA INDEX NAME)




RN 867376-35-0 HCAPLUS


CN Benzoic acid, 3-[2-[(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)amino]-2-oxoethoxy]-, ethyl ester (CA INDEX NAME)



IT 4122-68-3 15516-47-9
 (preparation of (heteroaryl) amides and hydrazides as inhibitors of phosphatase located on chromosome 10 (PTEN))
 RN 4122-68-3 HCPLUS
 CN Acetyl chloride, 2-(4-chlorophenoxy)- (CA INDEX NAME)



RN 15516-47-9 HCPLUS
 CN Acetyl chloride, 2-(4-methylphenoxy)- (CA INDEX NAME)



IC ICM A61K031-44
 CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 IT 604-95-5P 36043-49-9P 43100-25-0P 146903-18-6P
 162086-14-8P 220965-34-4P 303092-45-7P 345630-40-2P
 345630-42-4P 376383-76-5P 458553-48-5P 477847-81-7P
 478257-76-0P 511518-73-3P 547730-75-6P 650620-84-1P
 774184-51-9P 860207-88-1P 867339-05-7P 867375-71-1P
 867375-74-4P 867375-77-7P 867375-78-8P 867375-79-9P
 867375-82-4P 867375-88-0P 867375-89-1P 867375-90-4P
 867375-91-5P 867375-92-6P 867375-93-7P 867375-94-8P
 867375-96-0P 867375-97-1P 867375-99-3P 867376-00-9P
 867376-01-0P 867376-02-1P 867376-03-2P
 867376-04-3P 867376-05-4P 867376-06-5P
 867376-07-6P 867376-08-7P 867376-10-1P
 867376-11-2P 867376-12-3P 867376-13-4P
 867376-14-5P 867376-15-6P 867376-16-7P
 867376-17-8P 867376-18-9P 867376-19-0P
 867376-20-3P 867376-27-0P 867376-28-1P

867376-29-2P 867376-33-8P 867376-34-9P
 867376-35-0P 867376-36-1P 867376-37-2P 867376-38-3P
 867376-39-4P
 (preparation of (heteroaryl) amides and hydrazides as inhibitors of phosphatase located on chromosome 10 (PTEN))
 IT 79-04-9 95-54-5, 1,2-Benzenediamine, reactions 98-09-9, Benzenesulfonyl chloride 98-59-9, Tosyl chloride 98-74-8, 4-Nitrobenzenesulfonyl chloride 122-04-3, 4-Nitrobenzoyl chloride 122-59-8 452-58-4, 2,3-Pyridinediamine 496-72-0 586-75-4 610-14-0 619-05-6 694-83-7, 1,2-Diaminocyclohexane 701-99-5, Phenoxyacetyl chloride 874-60-2 939-97-9, 4-tert-Butylbenzaldehyde 1072-84-0, 4-Imidazolecarboxylic acid 1710-98-1, 4-tert-Butylbenzoyl chloride 1821-12-1, 4-Phenylbutyric acid 1878-49-5 2243-83-6, 2-Naphthoyl chloride 2687-25-4 2905-27-3 3282-30-2 4122-68-3 4755-77-5 5271-67-0, 2-Thiophenecarbonyl chloride 5315-25-3, 2-Bromo-6-methylpyridine 5437-45-6 13754-19-3, 4,5-Pyrimidinediamine 15084-51-2, 4-tert-Butylbenzenesulfonyl chloride 15516-47-9 16629-19-9, 2-Thiophenesulfonyl chloride 17325-26-7, Methyl imidazole-4-carboxylate 18496-54-3, 4-Phenylbutanoyl chloride 20142-87-4 40926-73-6 85397-21-3 106967-74-2 1042674-31-6 1042675-60-4
 (preparation of (heteroaryl) amides and hydrazides as inhibitors of phosphatase located on chromosome 10 (PTEN))

L31 ANSWER 5 OF 8 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:472654 HCPLUS Full-text
 DOCUMENT NUMBER: 135:61559
 TITLE: Preparation of phenanthrene-9,10-dione derivatives as CD45 inhibitors
 INVENTOR(S): Chapdelaine, Marc Jerome; Knappenberger, Katherine; Steelman, Gary; Suchard, Suzanne; Sygowski, Linda; Urbanek, Rebecca; Veale, Chris Allan
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046125	A2	20010628	WO 2000-GB4854	20001218
WO 2001046125	A3	20020117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1242363	A2	20020925	EP 2000-985603	20001218
EP 1242363	B1	20051102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518085	T	20030603	JP 2001-547036	20001218

AT 308512	T 20051115	AT 2000-985603	20001218
US 20030207812	A1 20031106	US 2002-168758	20021125
PRIORITY APPLN. INFO.:		US 1999-172788P	P 19991221
		WO 2000-GB4854	W 20001218

OTHER SOURCE(S): MARPAT 135:61559

ED Entered STN: 29 Jun 2001

GI




AB Substituted phenanthrene-9,10-diones I [R1 at each occurrence is independently selected from H, halogen, NH₂, NO₂, NHCOR₂, CONHR₂, Ar, (CH₂)_nCH(CO₂H)R₃, COR₃, NHCOCH₂CH(CO₂H)NHR₄ and NR₅₂, where R₂ = (un)substituted (C₁-C₄)alkyl, (C₁-C₈)alkylCO₂H or alkyl esters, Ph; n = 1-8; Ar = 3-thienyl, 2-benzofuranyl, 1-naphthyl, 1,3-benzodioxan-5-yl, or (un)substituted phenyl; R₃ = certain N-linked oligopeptides; R₄ = certain C-linked oligopeptides; R₅ = H, tosyl (with provisos)] were prepared for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. Thus, 9,10-dioxophenanthren-3-ylcarbonyl-Glu-Gln-Pro-Gln-Pro-OH was prepared by the solid-phase method and assayed for biol. activity (pNPP, lck, and T cell proliferation IC₅₀s are 0.6, 2.4, and >30 μM, resp. and CC₅₀ is >30 μM).


IT 36043-49-9P
(preparation of phenanthrenedione derivs. as CD45 inhibitors)

RN 36043-49-9 HCPLUS


CN 9,10-Phenanthrenedione, 2-amino- (CA INDEX NAME)



IT 604-95-5P 345630-42-4P
(preparation of phenanthrenedione derivs. as CD45 inhibitors)
RN 604-95-5 HCPLUS
CN 9,10-Phenanthrenedione, 2-nitro- (CA INDEX NAME)



RN 345630-42-4 HCAPLUS
 CN Benzamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2-nitro- (CA
 INDEX NAME)



IC ICM C07C237-00
 CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 1, 15, 25
 IT 604-94-4P 32060-67-6P 32155-34-3P 36043-49-9P
 47194-23-0P 49546-41-0P 51789-39-0P 53622-33-6P 109497-01-0P
 345631-37-0P 345631-41-6P 345631-42-7P
 (preparation of phenanthrenedione derivs. as CD45 inhibitors)
 IT 604-95-5P 4733-06-6P 7473-71-4P 13292-03-0P
 62896-78-0P 109313-55-5P 345630-35-5P 345630-37-7P
 345630-38-8P 345630-40-2P 345630-42-4P 345630-43-5P
 345630-44-6P 345630-45-7P 345630-46-8P 345630-47-9P
 345630-51-5P 345630-52-6P 345630-53-7P 345630-54-8P
 345630-55-9P 345630-56-0P 345630-57-1P 345630-58-2P
 345630-59-3P 345630-60-6P 345630-61-7P 345630-62-8P
 345630-63-9P 345630-64-0P 345630-65-1P 345630-66-2P
 345630-67-3P 345630-68-4P 345630-69-5P 345630-70-8P
 345630-71-9P 345630-72-0P 345630-73-1P 345630-74-2P
 345630-75-3P 345630-76-4P 345630-77-5P 345630-78-6P
 345630-79-7P 345630-80-0P 345630-81-1P 345630-83-3P
 345630-84-4P 345630-85-5P 345630-87-7P 345630-89-9P
 345630-91-3P 345630-93-5P 345630-95-7P 345630-97-9P
 345630-99-1P 345631-01-8P 345631-03-0P 345631-05-2P
 345631-07-4P 345631-09-6P 345631-11-0P 345631-12-1P
 345631-13-2P 345631-14-3P 345631-15-4P 345631-16-5P
 345631-17-6P 345631-18-7P 345631-19-8P 345631-20-1P
 345631-21-2P 345631-22-3P 345631-23-4P 345631-24-5P
 345631-25-6P 345631-26-7P 345631-27-8P 345631-28-9P
 345631-29-0P 345631-30-3P 345631-31-4P 345631-32-5P
 345631-33-6P 345631-34-7P 345631-35-8P 345631-36-9P
 345631-38-1P 345631-39-2P 345631-40-5P 345631-43-8P
 345631-44-9P
 (preparation of phenanthrenedione derivs. as CD45 inhibitors)

L31 ANSWER 6 OF 8 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:306240 HCPLUS Full-text
 DOCUMENT NUMBER: 135:70647
 TITLE: Potent Reversible Inhibitors of the Protein
 Tyrosine Phosphatase CD45
 AUTHOR(S): Urbanek, Rebecca A.; Suchard, Suzanne J.;
 Steelman, Gary B.; Knappenberger, Katharine S.;
 Sygowski, Linda A.; Veale, Chris A.; Chapdelaine,
 Marc J.
 CORPORATE SOURCE: AstraZeneca Pharmaceuticals, Wilmington, DE,
 19850, USA
 SOURCE: Journal of Medicinal Chemistry (2001), 44(11),
 1777-1793
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

ED Entered STN: 02 May 2001


AB The cytosolic portion of CD45, a major transmembrane glycoprotein found on nucleated hematopoietic cells, contains protein tyrosine phosphatase activity and is critical for T-cell receptor-mediated T-cell activation. CD45 inhibitors could have utility in the treatment of autoimmune disorders and organ graft rejection. A number of 9,10-phenanthrenediones were identified that reversibly inhibited CD45-mediated p-nitrophenyl phosphate (pNPP) hydrolysis. Chemical efforts around the 9,10-phenanthrenedione core led to the most potent inhibitors known to date. In a functional assay, the compds. were also potent inhibitors of T-cell receptor-mediated proliferation, with activities in the low micromolar range paralleling their enzyme inhibition. It was also discovered that the nature of modification to the phenanthrenedione pharmacophore could affect selectivity for CD45 over PTP1B (protein tyrosine phosphatase 1B) or vice versa.

IT 36043-49-9P

(preparation and structure activity relationships of phenanthrenediones as inhibitors of protein tyrosine phosphatase CD45)

RN 36043-49-9 HCPLUS

CN 9,10-Phenanthrenedione, 2-amino- (CA INDEX NAME)




IT 604-95-5P

(preparation and structure activity relationships of phenanthrenediones as inhibitors of protein tyrosine phosphatase CD45)

RN 604-95-5 HCPLUS

CN 9,10-Phenanthrenedione, 2-nitro- (CA INDEX NAME)



CC 1-3 (Pharmacology)

Section cross-reference(s): 25

IT 604-94-4P 32155-34-3P 36043-49-9P 53622-33-6P
345631-41-6P(preparation and structure activity relationships of phenanthrenediones
as inhibitors of protein tyrosine phosphatase CD45)IT 604-95-5P 607-09-0P 13292-03-0P 32060-67-6P
47194-23-0P 51789-39-0P 62896-78-0P 73671-07-5P 109497-01-0P

137354-59-7P 345224-95-5P 345224-96-6P 345224-97-7P

345224-98-8P 345224-99-9P 345630-35-5P 345630-37-7P

345630-38-8P 345630-40-2P 345630-43-5P 345630-46-8P

345630-52-6P 345630-53-7P 345630-54-8P 345630-55-9P

345630-56-0P 345630-58-2P 345630-60-6P 345630-61-7P

345630-62-8P 345630-66-2P 345630-67-3P 345630-68-4P

345630-69-5P 345630-70-8P 345630-71-9P 345630-72-0P

345630-73-1P 345630-74-2P 345630-75-3P 345630-76-4P

345630-77-5P 345630-78-6P 345630-79-7P 345630-80-0P

345630-81-1P 345630-82-2P 345630-84-4P 345630-85-5P

345630-86-6P 345630-88-8P 345630-90-2P 345630-92-4P

345630-94-6P 345630-96-8P 345630-98-0P 345631-00-7P

345631-02-9P 345631-04-1P 345631-06-3P 345631-08-5P

345631-10-9P 345631-12-1P 345631-13-2P 345631-14-3P

345631-15-4P 345631-16-5P 345631-25-6P 345631-31-4P

345631-32-5P 345631-35-8P 345631-37-0P 345631-38-1P

345631-39-2P 345631-42-7P 345631-43-8P 345631-44-9P

346717-82-6P 346717-83-7P

(preparation and structure activity relationships of phenanthrenediones
as inhibitors of protein tyrosine phosphatase CD45)REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L31 ANSWER 7 OF 8 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1922:15423 HCPLUS Full-text

DOCUMENT NUMBER: 16:15423

ORIGINAL REFERENCE NO.: 16:2684h-i,2685a-i

TITLE: Amino- and anilinophenanthrenequinones

AUTHOR(S): Brass, Kurt; Ferber, Erwin

SOURCE: Berichte der Deutschen Chemischen Gesellschaft

[Abteilung] B: Abhandlungen (1922), 55B, 541-56

CODEN: BDCBAD; ISSN: 0365-9488

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

ED Entered STN: 16 Dec 2001

AB cf. C. A. 14, 3070. 2-Bromophenanthrenequinone (A), treated with PhNH₂, PhNH₂.HCl or 2PhNH₂.H₂SO₄ under ordinary conditions, under pressure or in PhNO₂ as a diluent, does not react with elimination of HBr, but the A acts as an oxidizing agent and the resulting dark blue to black products are substances closely related to aniline black. If they are freed from the

excess of PhNH₂ and the unchanged A is removed with alkaline Na₂S₂O₄, they can easily be oxidized to benzoquinone with CrO₃; the 2-bromophenanthrenequinol (B) formed simultaneously, however, also reacts with any PhNH₂ still present with the formation of phenylaminohydroxyphenanthrene. The same results are obtained when AcNHPH or its Na salt or the Na or Al salts of PhNH₂ are used instead of PhNH₂. The monophenylhydrazone of A does not react with PhNH₂ in the desired sense, nor does the dibenzoate of B. Recourse was then had to the phenylation of aminophenanthrenequinones. 2- and 4-Nitrophenanthrenequinones are obtained in 20 and 13 g. yields, resp., by nitration of 30 g. phenanthrenequinone. The 2-NO₂ compound (5 g.), rubbed to a thin paste with 250 cc. NaOH (d. 1.065), slowly treated with somewhat more than 4 mols. solid Na₂S₂O₄, warmed a short time at 50°, diluted, filtered and treated with air, gives 3.6 g. of the 2-NH₂ compound (C), also obtained in 3.9 g. yield from 5 g. of the NO₂ compound in much H₂O quickly treated with a solution of NaSH prepared from 1.6 g. NaOH, shaken 0.5 hr. in a tightly stoppered flask, diluted and treated with air; it seps. from H₂O in slender black-violet needles, brown in transmitted light, sinters 205-10°, gradually softens but does not m. clear 300°, soluble in concentrated H₂SO₄ with red-brown, in H₂SO₄ diluted with 0.25 part H₂O with cress-red, in fuming acid (20% SO₃) with green color; acetyl derivative (D), obtained with Ac₂O in boiling AcOH, red-violet needles from the red-brown solution in PhNO₂, m. 324° (decomposition), soluble in concentrated H₂SO₄ with brown, in H₂SO₄-H₂O (4 : 1) with red-brown, in fuming acid with green color, easily forms a yellow vat from which it is repptd. unchanged (passing through green) by air, dyes cotton a dirty salmon-red; benzoyl derivative, prepared with BzCl in hot C₅H₅N, flat brown-red spears from PhNO₂, m. 297-8°, soluble in H₂SO₄ with green-brown color, forms a deep-yellow vat which dyes cotton a turbid light red. 2-Acetylaminophenanthrenequinol, from C in a little AcOH heated a short time with excess of Ac₂O and then boiled about 0.5 hr. with Fe filings, fine white needles from EtOH-H₂O, m. 228°, subliming in silky needles, gradually dissolves in concentrated H₂SO₄ with green color. 4-Aminophenanthrenequinone, obtained almost quant. from the NO₂ compound with NaSH and subsequent treatment with air, violet-brown crystalline meal with metallic luster from H₂O, black warty aggregates from 96% alc., softens 207°, does not m. 340°, easily soluble in the usual solvents with intense red, in concentrated H₂SO₄ with yellow-olive, in more dilute acid (4 : 1) with red-brown color. 2-Ethylaminophenanthrenequinone, from 1.7 g. D and 0.9 g. EtBr heated 5.5 hrs. at 180° in C₅H₅N in a sealed tube, poured into much dilute HCl, filtered and deacetylated by boiling 1.5 hrs. with 1 : 1 H₃PO₄, violet-black powder, soluble in hot AcOH, PhNO₂ and C₅H₅N with brown color, seps. from PhNO₂ in crystalline warts, has no m. p. 2-Anilinophenanthrenequinone, from equimol. amts. of C and PhBr, with a little Cu powder, heated 4 hrs. at 200° in C₅H₅N, black, almost insol. powder, soluble in cold concentrated H₂SO₄ with dirty brown color, forms a vat with very great difficulty in aqueous, easily in aqueous alc. suspension, has no m. p., is almost insol. in aqueous or alc. KOH. 2',4'-Dinitro-2-anilinophenanthrenequinone, obtained (together with some [(O₂N)2C₆H₃-]2, m. 143°) from 1 mol. each of C and 2,4-(O₂N)2C₆H₃Cl, with a little CaCO₃ and Cu powder boiled 1.5 hrs. in PhNO₂, brown spear- and table-like crystals from PhNO₂, m. 280°, soluble in concentrated H₂SO₄ with brown color, forms a vat in alkaline Na₂S₂O₄, does not react with o-C₆H₄(NH₂)₂, forms in cold aqueous alc. KOH a salt recognized by the intense red color imparted to the solution, gives 2,4-(O₂N)2C₆H₃OH with K₂Cr₂O₇-H₂SO₄ (no diphenic acid could be detected); 1 g. heated 1 hr. at 80° with 100 cc. of 10% KOH gives 2',4'-dinitro-2-anilinodiphenylglycolic acid, brown amorphous powder, has no m. p., soluble in concentrated H₂SO₄ with red-brown color, forms easily soluble alkali and insol. Pb, Cu and Ag salts. 2',4',6'-Trinitro-2-anilinophenanthrenequinone, from C and 1 mol. picryl chloride, with a little NaOAc and a trace of Cu powder, refluxed 3 hrs. in alc., sandy powder of small red-brown table-like crystals or a red to red-brown amorphous powder, m. 304-5°, soluble in concentrated H₂SO₄ with yellow-green color, repptd. unchanged


by H₂O, forms a vat with alkaline Na₂S₂O₄ but gives no quinoxaline with o-C₆H₄(NH₂)₂, oxidized by K₂Cr₂O₇-H₂SO₄ to picramide, gives with aqueous KOH 2',4',6'-trinitro-2-anilinodiphenyleneglycolic acid, does not m., decomp. 300° (heated in larger amts. in an open test-tube it deflagrates explosively at 160°).

IT 860207-88-1P, Benzamide,

N-(9,10-dihydro-9,10-diketo-2-phenanthryl)-
(preparation of)

RN 860207-88-1 HCPLUS

CN Benzamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)- (CA INDEX
NAME)



CC 10 (Organic Chemistry)

IT 4733-06-6P, Acetamide, N-(9,10-dihydro-9,10-diketo-2-phenanthryl)-

4733-06-6P, Phenanthrenequinone, 2-acetamido- 109497-01-0P,
Phenanthrenequinone, 4-amino- 860207-88-1P, Benzamide,

N-(9,10-dihydro-9,10-diketo-2-phenanthryl)- 860207-88-1P,

Phenanthrenequinone, 2-benzamido- 861321-00-8P, 9-Fluorenecarboxylic
acid, 9-hydroxy-2-(2,4,6-trinitroanilino)- 861337-30-6P,

Phenanthrenequinone, 2-anilino- 861349-60-2P, Phenanthrenequinone,
2-(2,4,6-trinitroanilino)- 861349-63-5P, Phenanthrenequinone,

2-ethylamino- 861350-08-5P, Acetamide,

N-(9,10-dihydroxy-2-phenanthryl)-, diacetate 861350-08-5P,

9,10-Phenanthrenediol, 2-acetamido-, diacetate 861373-57-1P,

9-Fluorenecarboxylic acid, 2-(2,4-dinitroanilino)-9-hydroxy-
861798-82-5P, Phenanthrenequinone, 2-(2,4-dinitroanilino)-

(preparation of)

L31 ANSWER 8 OF 8 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1916:14053 HCPLUS Full-text

DOCUMENT NUMBER: 10:14053

ORIGINAL REFERENCE NO.: 10:2583a-i,2584a-c

TITLE: Dyes derived from phenanthraquinone

AUTHOR(S): Mukherjee, Kshitish C.; Watson, Edwin R.

CORPORATE SOURCE: Dacca, Bengal, India

SOURCE: Journal of the Chemical Society, Transactions
(1916), 109, 617-28

CODEN: JCHTA3; ISSN: 0368-1645

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

ED Entered STN: 16 Dec 2001

AB A study undertaken because of the close relationship of phenanthraquinone (A) to anthraquinone (B). The methods of introducing additional HO groups used in the (B) series failed, owing to the feebler resistance of the (A) series, but the methods used for the production of anilino derivs. (Ullmann, Ber. 34, 2174(1901), and D. R. P. 113,011) were applicable. Attempts to obtain vat dyes from acylamino derivs. were not encouraging. 15 g. fuming H₂SO₄ (SO₃ =


70%) were added to 1.5 g. 2-hydroxyphenanthraquinone in a small stoppered bottle which was kept closed at 35-40° for 48 hrs.; the resulting acid was isolated as barium 2-hydroxyphenanthraquinonesulfonate, violet, soluble in boiling H₂O, insol. in absolute alc. 3 g. 2,7-diacetoxyphenanthraquinone in 30 cc. HNO₃ (d. 1.39) were warmed to 50-60° for 1.5 min. by immersion in boiling H₂O, followed by immediately pouring into H₂O, giving nitro-2,7-diacetoxyphenanthraquinone, yellow-brown prisms, does not m. 290°; boiled in HOAc containing a few drops H₂SO₄ it yields nitro-2,7-dihydroxyphenanthraquinone (C), brown, does not m. below 290°. (C), heated on the H₂O bath with Sn and concentrated HCl, did not dissolve, but turned first deep brown and then light brown; then warmed first with aqueous FeCl₃ solution and boiled with dilute HCl until ash-free it gave amino-2,7-dihydroxyphenanthraquinone, plates, does not m. 290°, insol. in organic solvents, soluble in alkalies with a brown color; triacetyl derivative, amorphous; diazotization and boiling gave 2,4(?),7-trihydroxyphenanthraquinone, red-brown, does not m. 290°, soluble in alkalies with a brown color; triacetate, red-brown microcrystals, m. about 280°. 2,7-Diaminophenanthraquinone, NaOAc, and Ac₂O heated at 160° for 1 hr., mixed with an equal volume of HOAc, and poured into H₂O, gave the diacetamino derivative, chocolate-brown crystals, does not m. below 295°. 1 g. dibromophenanthraquinone (D), from (A) in PhNO₂ with Br (D. R. P. 222,206), when boiled with 35 cc. HNO₃ (d. 1.42) for 0.5 hr. and the solution poured into H₂O, gave dibromonitrophenanthraquinone, yellow needles, m. 244-5°; 1 g. (D), boiled 2 min. with 10 cc. fuming HNO₃ (d. 1.51) and 1.5 cc. H₂SO₄ and poured into H₂O gave bromodinitrophenanthraquinone, yellow needles, m. above 300°. 2-Nitrophenanthraquinone (1 g.), 0.6 g. Br, and 6 cc. HOAc at 140° for 2 hrs. gave bromo-2-nitrophenanthraquinone (E), red-yellow plates, m. above 300°. 1 g. 4-nitrophenanthraquinone treated with excess of Br at 110° in as little PhNO₂ as possible gave the bromo derivative, yellow prisms, m. 224-6°; 1 g. 2,7-dibromophenanthraquinone, 10 g. PhNH₂, and 0.25 g. Cu powder were boiled for 2.5-3 hrs., filtered hot, and poured into an excess of dilute HCl; the resulting blue-black 2,7-dianilinophenanthraquinone does not m. below 300° and dyes wool blue-black shades. Similarly (D) gives a bluish dianilinophenanthraquinone, does not m. below 300° and dyes wool greenish blue shades; (E) yielded 2-nitroanilinophenanthraquinone (F), blue-black, does not m. below 300°, dyes wool blue-black shades; 4-nitroanilinophenanthraquinone, black, does not m. below 300°, dyes wool blackish shades; dinitroanilinophenanthraquinone, black, gives greenish black shades on wool; nitrodianilinophenanthraquinone, dyes wool in black shades. Dianilinophenanthraquinone, heated with 10 parts H₂SO₄ (d. 1.84) at 110-20° for 1 hr. gives a sulfonic acid which dyes faster, greener shades than the parent substance. Similarly, at 125-30° for 2 hrs. (F) gives a sulfonic acid which dyes chrome-mordanted wool in olive-green shades. 1 g. (D), 1 g. p-O₂NC₆H₄NH₂, 5 cc. PhNMe₂, and a trace of Cu powder heated at 160° for 3.5 hrs. and poured into dilute HCl gave bromo-p-nitroanilinophenanthraquinone, reddish violet, does not m. 280°, does not dye wool. 1 g. (D), 1.5 g. (C₆H₄NH₂)₂, 2 g. fused NaOAc, 0.35 g. CuCl₂, and 20 g. PhNO₂ boiled for 2 hrs., precipitated with Et₂O, washed with alc., and boiled with H₂O gave dibenzidinophenanthraquinone, black powder, does not m., does not dye wool. 2-Aminophenanthraquinone and BzCl in PhNO₂ at 100° for 20 min. gave the benzoyl derivative, pinkish needles, m. 295°; as a vat dye it gives pale pink shades on cotton; 2-phthalylaminophenanthraquinone, pale orange needles, does not m. 295°, dyes cotton pale yellow in the vat; 2-oxarylaminophenanthraquinone, red-brown needles, does not m. 295°, does not dye cotton. 2,7-Dibenzoyldiaminophenanthraquinone, using BzCl in boiling PhNO₂, brick-red needles, does not m. 295°, in the vat gives brown-orange shades on cotton; 2,7-diphthalylaminophenanthraquinone, brick-red needles, does not m. 295°, is not absorbed from the vat by cotton; 2,7-diaminophenanthraquinonesulfonic acid, using excess of fuming acid (SO₃ = 70%) in a closed bottle for 48 hrs.

and pouring into H₂O; in the moist state it dyes alummordanted wool dull green shades. Phenanthraquinonebisazophenol, diazotizing in 5% H₂SO₄ suspension, adding to a PhOH solution, and carefully making alkaline with Na₂CO₃, lenticular crystals, does not m. 295°, soluble in alkalies with a brown color; boiling with Ac₂O and a drop of C₅H₅N and precipitating with alc. gives the acetate, brick-red prisms, m. 274°.

IT 860207-88-1P, Phenanthrenequinone, 2-benzamido-
(preparation of)

RN 860207-88-1 HCPLUS

CN Benzamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)- (CA INDEX
NAME)



CC 10 (Organic Chemistry)

IT 49546-41-0P, Phenanthrenequinone, 2,7-diamino-, diaceto derivative

860207-88-1P, Phenanthrenequinone, 2-benzamido-

860208-68-0P, Phenanthrenequinone, 2,4,7-trihydroxy-, triaceto derivative

860208-68-0P, Phenanthrenequinone, 2,4,7-trihydroxy- 860208-69-1P,

Phenanthrenequinone, 2-(phthalylamino)- 860208-70-4P,

Phenanthrenequinone, 2,7-dibenzamido- 860768-28-1P,

Phenanthrenequinone, 2,7-bis(phthalylamino)- 860768-29-2P,

Phenanthrenequinone, anilino-4-nitro- 871902-28-2P,

Phenanthrenequinone, 2,7-dianilino-

(preparation of)

=> d his nofile

(FILE 'HOME' ENTERED AT 08:44:52 ON 17 DEC 2008)

FILE 'HCAPLUS' ENTERED AT 08:45:03 ON 17 DEC 2008

L1 1 SEA ABB=ON PLU=ON US20070203098/PN
SEL RN

FILE 'REGISTRY' ENTERED AT 08:45:18 ON 17 DEC 2008

L2 190 SEA ABB=ON PLU=ON (1042674-02-1/BI OR 1042674-31-6/BI OR
1042675-60-4/BI OR 10453-86-8/BI OR 106967-74-2/BI OR
1072-84-0/BI OR 115926-52-8/BI OR 122-04-3/BI OR 122-59-8/B
I OR 129-46-4/BI OR 129318-43-0/BI OR 130-15-4/BI OR
13754-19-3/BI OR 145-73-3/BI OR 146903-18-6/BI OR 150560-58
-0/BI OR 15084-51-2/BI OR 15516-47-9/BI OR 16037-91-5/BI
OR 162086-14-8/BI OR 16629-19-9/BI OR 1710-98-1/BI OR
17325-26-7/BI OR 17630-76-1/BI OR 1821-12-1/BI OR 18496-54-
3/BI OR 18711-13-2/BI OR 1878-49-5/BI OR 20142-87-4/BI OR
2058-74-4/BI OR 20780-76-1/BI OR 220965-34-4/BI OR
2243-83-6/BI OR 237756-11-5/BI OR 2632-13-5/BI OR 2650-44-4
/BI OR 2687-25-4/BI OR 27318-90-7/BI OR 2905-27-3/BI OR
296771-71-6/BI OR 296773-88-1/BI OR 301166-54-1/BI OR
303092-45-7/BI OR 303149-87-3/BI OR 303998-01-8/BI OR
304883-18-9/BI OR 311321-81-0/BI OR 312519-17-8/BI OR
315671-49-9/BI OR 3282-30-2/BI OR 339205-70-8/BI OR
339205-73-1/BI OR 345630-40-2/BI OR 345630-42-4/BI OR
36043-49-9/BI OR 376383-76-5/BI OR 39755-95-8/BI OR
401646-54-6/BI OR 40926-73-6/BI OR 4122-68-3/BI OR
42494-71-3/BI OR 42494-73-5/BI OR 43100-25-0/BI OR
43100-38-5/BI OR 443-69-6/BI OR 452-58-4/BI OR 458553-48-5
/BI OR 4755-77-5/BI OR 477847-81-7/BI OR 478063-72-8/BI OR
478077-73-5/BI OR 478077-74-6/BI OR 478077-78-0/BI OR
478077-79-1/BI OR 478257-55-5/BI OR 478257-73-7/BI OR
478257-76-0/BI OR 484-17-3/BI OR 496-72-0/BI OR 511518-73-3
/BI OR 512796-41-7/BI OR 512796-49-5/BI OR 512796-50-8/BI
OR 512796-65-5/BI OR 512796-67-7/BI OR 512796-72-4/BI OR
512796-76-8/BI OR 512796-99-5/BI OR 51630-58-1/BI OR
52315-07-8/BI OR 524-42-5/BI OR 5271-67-0/BI OR 52918-63-5
/BI OR 5315-25-3/BI OR 5437-45-6/BI OR 547730-75-6/BI OR
5725-96-2/BI OR 585557-83-1/BI OR 586-75-4/BI OR 5908-27-0/
BI OR 604-95-5/BI OR 610-14-0/BI OR 611-09-6/BI OR
619-05-6/BI OR 650620-84-1/BI

L3 1 SEA ABB=ON PLU=ON L2 AND C22 H15 N 04/MF

FILE 'HCAPLUS' ENTERED AT 08:48:30 ON 17 DEC 2008

L4 1 SEA ABB=ON PLU=ON L3

FILE 'REGISTRY' ENTERED AT 08:48:57 ON 17 DEC 2008

E C22 H15 N 04/MF

L5 409 SEA ABB=ON PLU=ON "C22 H15 N 04"/MF
L6 39 SEA ABB=ON PLU=ON L5 AND 10-DIOXO?
L7 59167 SEA ABB=ON PLU=ON 2404.11/RID
L8 512 SEA ABB=ON PLU=ON L7 AND 9,10-DIOXO?
L9 1 SEA ABB=ON PLU=ON L8 AND 2-PHENOXY?
L10 8 SEA ABB=ON PLU=ON L8 AND PHENOXY?

FILE 'HCAPLUS' ENTERED AT 08:52:45 ON 17 DEC 2008

L11 2 SEA ABB=ON PLU=ON L10

FILE 'REGISTRY' ENTERED AT 08:54:33 ON 17 DEC 2008

L12 32 SEA ABB=ON PLU=ON L2 AND L7
L13 8 SEA ABB=ON PLU=ON L12 AND PHENOXY?
L14 8 SEA ABB=ON PLU=ON L10 AND L13
L15 0 SEA ABB=ON PLU=ON L12 AND BENZOXY?
L16 0 SEA ABB=ON PLU=ON L12 AND BENZYLOXY?
L17 0 SEA ABB=ON PLU=ON L8 AND BENZYLOXY?
L18 1 SEA ABB=ON PLU=ON L2 AND C14 H9 N O2/MF
L19 1 SEA ABB=ON PLU=ON L2 AND C8 H6 CL2 O2/MF
L20 1 SEA ABB=ON PLU=ON L2 AND C9 H9 CL O2/MF
L21 1 SEA ABB=ON PLU=ON L2 AND C14 H7 N O4/MF

FILE 'HCAPLUS' ENTERED AT 09:06:30 ON 17 DEC 2008

L22 2935 SEA ABB=ON PLU=ON L12
L23 59 SEA ABB=ON PLU=ON L18 OR L21
L24 377 SEA ABB=ON PLU=ON L19 OR L20
L25 1 SEA ABB=ON PLU=ON L23 AND L24

FILE 'REGISTRY' ENTERED AT 09:07:35 ON 17 DEC 2008

L26 26 SEA ABB=ON PLU=ON L12 NOT S/ELS
L27 17 SEA ABB=ON PLU=ON L26 AND 4/NR

FILE 'HCAPLUS' ENTERED AT 09:08:20 ON 17 DEC 2008

L28 5 SEA ABB=ON PLU=ON L27
L29 5 SEA ABB=ON PLU=ON L11 OR L28 OR L25
L30 5 SEA ABB=ON PLU=ON L23 AND PHARM?/SC, SX
L31 8 SEA ABB=ON PLU=ON L29 OR